Good news for women after hysterectomy, who are going to take the hormone estrogen to relieve hot flashes and other complications associated with menopause.New results of a long study of the influence of the government of hormones on women's health indicate that estrogen is likely to reduce by 20% the risk of developing breast cancer in women, and also significantly reduces the risk of death from this disease.This beneficial effect lasts for many years after the end of therapy."Hormone therapy definitely improves the quality of life for some women," - says Margery Gass.She is the executive director of the North American Menopause Society for the Study (NAMS).
NAMS recently amended the statement of its position regarding the use of hormone replacement therapy, according to new study data.In 2002, a doctor familiar with these studies "initiative in the name of women's health," sounded the alarm, warning that the risk of heart attack, stroke and breast cancer in women taking estrogen combined with progesti
However, experts say that the initial response to hormonal therapy, most likely has not been confirmed.According to them, many women are not afraid to take hormones for a short period of time to suppress severe hot flashes, night sweats and mood swings that may accompany menopause."The difference in the impact of breast cancer estrogen combined with progestin and estrogen alone is so significant that we felt it was time to report that women taking estrogen alone can not stop taking it for 3-5 years.Since during this period among women taking estrogen alone, cases of breast cancer were detected, "- says Gass, who is also the co-author of the new study.
Together estrogen and progestin are appointed, as a rule, women with a uterus, increasing the benefit to estrogen therapy, reduce the risk of uterine cancer.Separately, the estrogen used to treat women who have had a hysterectomy, or removal of the uterus.Statistics show that in the US, about one-third of women suffer a hysterectomy at the time of achieving the age of 60.
results undoubtedly very encouraging
In the latest study, published in the journal "The Lancet.Oncology "scientists have observed in more than 7,600 women who were part of the study participants, which was dedicated to the study of the effect of treatment with estrogen.Women who have been appointed as estrogen, a hormone that took about six years.Watching them after stopping estrogen is carried out at the moment for the past almost five years.Compared with women taking placebo, those women who took estrogen, the risk of invasive breast cancer was reduced by 23%.This means that in the group member who take estrogen, breast cancer developed in 151 women, while in the placebo group was 199 cases.
Also, women taking estrogen, the risk of death from breast cancer was reduced by 63% compared with the placebo-group participants.In total, the group treated with estrogen, there were 6 deaths, whereas in the placebo group - 16 Anthony Howell, MD, Professor of Medical Oncology at the University of Manchester in the UK, says in an email that the study results certainly very encouraging forwomen.
«However, consultations should be held with respect to a very small increased risk of deep vein thrombosis (blood clots in the veins) and pulmonary embolism (blockage of blood vessels of the lungs), which is observed when taking any hormones, such as oral contraceptives," - says Howellwho commented on the findings, however, participate in the study did not take.
Benefits against breast cancer can spread not at all
Some also covers some important warnings.First, estrogen helped, apparently, not all women.First of all women with breast cancer risk was increased as this disease is present in their family history, or they had benign breast.Estrogen may even increase the risk of breast cancer in women who already have other risk factors."For women who most need the means to reduce the risk of breast cancer, this method will not work", - says Garnet L. Anderson, MD, principal investigator of the Clinical Center to coordinate research "initiative in the name of women's health" inSeattle.
«These substances should not be used to prevent breast cancer, despite the fact that research clearly shows that the risk of cancer in women taking hormones, reduced", - says Anderson, who is also a member of the Cancer Research Center.Fred Hutchinson.
Secondly, it is important to take into account that the study tested conjugated equine estrogen, which is sold under the trade name "Premarin".Over the past few years, the formulation of the drug is gaining less popular.Increasingly, women are moving to estradiol, which is the chemical composition closer to the estrogen produced by the body.However, researchers say they are not sure that these two types of estrogen are the same."Conjugated equine estrogens - it is very difficult pill" - says Anderson."They contain a large number of different estrogen compounds.And we do not know which substances are effective.Therefore, to talk about another form of estrogen is difficult. "